Tibra Equities Europe’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Tibra Equities Europe’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-24,300	Closed	-$1.78M	–	154
2020 Q4	$1.78M	Buy	+24,300	New	+$1.81M	0.18%	62
2019 Q3	–	Sell	-238,900	Closed	-$5.75M	–	385
2019 Q2	$5.75M	Buy	238,900 +223,100	+1,412%	+$5.66M	0.43%	62
2019 Q1	$418K	Buy	+15,800	New	+$374K	0.04%	282

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Tibra Equities Europe's HZNP Position: Q1 2021 in Review

Tibra Equities Europe sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2021, closing a stake of 24,300 shares — an estimated $1.78M sold.

Tibra Equities Europe first reported a position in HZNP in Q1 2019 and held it in 3 quarters. The position peaked at $5.75M in Q2 2019. 516 funds tracked by Wall St. Rank hold HZNP as of Q1 2021.

Tibra Equities Europe reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2021 after selling out during the quarter.
Tibra Equities Europe sold 24,300 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2021, an estimated $1.78M.
Tibra Equities Europe first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019 and held it in 3 quarters.
Tibra Equities Europe's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5.75M in Q2 2019.
516 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2021.

Based on Tibra Equities Europe's 13F filing for Q1 2021, filed 17 May 2021.